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Abstract
Tremendous excitement has been generated by the use of botulinum toxin for the treatment of
various types of urethral and bladder dysfunction over the past several years. Botulinum toxin is
the most lethal naturally occurring toxin known to mankind. Why, then, would an urologist want
to use this agent to poison the bladder or urethral sphincter? In this review article we will examine
the mechanisms underlying the effects of botulinum toxin treatment. We will discuss the current
use of this agent within the urologic community and will provide perspectives on future targets of
botulinum toxin.
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Tremendous excitement has been generated by the use of botulinum toxin for the treatment of various types of urethral and bladder dysfunction over the past several years. Botulinum toxin is the most lethal naturally occurring toxin known to mankind. Why, then, would an urologist want to use this agent to poison the bladder or urethral sphincter?In this review article we will examine the mechanisms underlying the eﬀects of botulinum toxin treatment. We will discuss the current use of this agent within the urologic community and will provide perspectives on future targets of botulinum toxin.
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T he world’s most potent biological toxin, botulinum toxin, was ﬁrst isolated in 1897 by van Ermen-
gem［1］. The toxin acts by inhibiting acetylcholine release at the presynaptic cholinergic junction. In the late 1980s the urologic community began to explore the use of botulinum toxin type A (BTX-A) to treat spinal cord injured patients suﬀering from detrusor external sphincter dyssynergia (DESD)［2-4］. A resurgence of interest over the past 5 years was led by Schurch and colleagues who reported successful treatment of spinal cord injured patients with detrusor hyperreﬂexia using intravesical BTX-A injections at multiple sites［5］.
History of Botulinum Toxin’s Medical Develop ment
-
Botulinum poisoning was ﬁrst described in cases of sausage poisoning in the late 1700s in Germany. A local medical oﬃcer collected data on 230 cases of botulism,
and the illness became known as“Kerner’s disease”［6］.
It wasn’t until 1897 that van Ermengem isolated the spore-forming obligate anaerobic bacteria, Clostridium botulinum［1］.
Botulinum toxins are synthesized as single chain polypeptides with a molecular weight of approximately 150 kilodaltons(kDa)［7］. Initially, the parent chain is cleaved into its active, dichain polypeptide form consisting of a heavy chain (approx. 100 kDa) connected by a disulﬁde bond to a light chain(approx. 50 kDa)with an associated zinc atom (Fig. 1)［8］. Three steps are required for toxin induced paralysis:1. binding and internalization of the toxin within the nerve terminal;2.
translocation of the light chain into the cytosol;and 3.
inhibition of neurotransmitter release.
Acetylcholine release involves the ATP-dependent
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transport of the vesicle from the cytosol to the plasma membrane［9］. Vesicle docking requires the interaction of various cytoplasmic, vesicle, and target membrane proteins, some of which are speciﬁcally targeted with clostridial neurotoxins. BTX-A, for example, cleaves the
 
cytosolic translocation protein SNAP-25, thus preventing vesicle fusion with the plasma membrane(Fig. 2)［10］.
Diﬀerent Applications of Botulinum Toxin
 
Seven immunologically distinct neurotoxin types are known and are typically labeled from A-G. BTX-A
(Botox?, Allergan Irvine, CA, USA)received FDA approval in 1989 for the treatment of strabismus, benign essential blepharospasm, and disorders of the VIIth nerve. Since its introduction into clinical use in the 1980s,
BTX-A has been successfully used to treat various conditions, including blepharospasm, strabismus, focal dystonias, muscle spasms and spasticity, axillary hyper-
hidrosis, and achalasia［11-15］. More recently, the U.S. FDA approved a BTX-B complex preparation
(MyoblocTM, Elan South San Francisco, CA, USA)for clinical use in cervical dystonia patients.
Botulinum Toxin’s Urologic Applications
 
Urological applica-
tions of BTX-A have been primarily associated with cases of Detrusor External Sphincter Dyssynergia (DESD).
Management of spinal cord injured (SCI)patients was revolutionized with the development of clean intermittent
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Fig.2  Schematic diagram of a nerve terminal indicating the blocking eﬀects of botulinum toxin on normal fusion of the synaptic vesicles with the plasma membrane. Note that after blocking of the vesicle transport by botulinum toxin, no ACh release occurs, leading to muscle atrophy.
Fig.1  This illustration depicts the active, dichain polypeptide form of botulinum toxin. The parent chain is cleaved into a heavy chain
(approx. 100 kDa)connected by a disulﬁde bond to a light chain
(approx. 50 kDa)with an associated zinc atom.
2
Acta Medica Okayama, Vol. 56 [2002], Iss. 6, Art. 1
http://escholarship.lib.okayama-u.ac.jp/amo/vol56/iss6/1
catheterization(CIC)by Lapides in 1971［16］. However,
not all patients can tolerate CIC and require an alternative that decreases outlet resistance and allows continuous bladder decompression. Various alternatives have been described, including external sphincterotomy, radical TURP, and various denervation procedures, i.e. dorsal rhizotomy［17］. These procedures are unfortunately permanent and irreversible, and carry with them inherent risks (i.e. bleeding, stricture formation, ﬁstulas).
BTX-A represents a viable option in the treatment of DESD. The toxin acts at the neuromuscular junction of the external sphincter to block vesicle transport of acetyl-
choline, in essence producing chemical denervation. The clinical eﬀects begin within 2-3 days and are reversible as terminal nerve sprouting occurs within 3-6 months［18］.
Injection of BoNT/A (i.e. BoNT＝laboratory grade botulinum toxin)into the sternomastoid muscle of mice has been shown to induce the formation of terminal nerve sprouts from the parent terminal［19］. The sprouts form functional synapses with the muscle but eventually regress at a time when the parent nerve terminal regains the ability to release neurotransmitters. It remains to be seen whether similar processes occur in autonomic nerves innervating the lower urinary tract.
Dykstra has investigated the eﬀects of BTX-A injec-
tion in 2 studies of SCI patients with DESD. In the ﬁrst
 
study, published in 1988, all 10 patients evaluated by electromyography after injection showed signs of sphinc-
ter denervation［4］. The urethral pressure proﬁle decreased by an average of 27 cm of water, and post void residuals decreased by an average of 146 cc after toxin injection. In 1990, Dykstra reported the results of the only double-blind placebo controlled study of BTX-A injection into the external urethral sphincter of 5 men with SCI and DESD［3］. Electromyography of the external urethral sphincter indicated denervation in the３ patients who received toxin injections. The urethral pressure proﬁle decreased by an average of 25 cm/H?O;the post void residual decreased by an average of 125 ml;and bladder pressure during voiding decreased to an average of 30 cm/H?O. Parameters were unchanged from baseline in the 2 patients who received normal saline injections.
We performed a prospective study on 21 patients referred to our clinic with voiding dysfunction［20］. All patients were evaluated with video-urodynamics. Follow-
up ranged from 3-16 months. Following urethral injec-
tion of Botox?, voiding pressures decreased by an average of 38 . Sixty-seven percent of patients reported an improvement in voiding patterns. No complications or side eﬀects were noted. Our results are consistent with the largest series to date treating DESD with BTX-A. In that study, Schurch treated 24 patients with SCI and DESD with BTX-A injection［21］. Signiﬁcant improve-
ment in DESD was noted in 21/24 pts (88 ) with decreased post void residuals in most patients. The eﬀects lasted 3-9 months with no adverse events report-
ed. Thus, BTX-A toxin injections appear to be a safe and eﬃcacious treatment option for DESD.
The clinical success of BTX-A is supported by labora-
tory research demonstrating marked decreases in the release of labeled norepinephrine and acetylcholine in BoNT/A injected rat urethral sphincters［22］. While the therapeutic eﬀects of inhibiting acetylcholine release are obvious, blockage of norepinephrine release may also provide clinical beneﬁts by inhibiting sympathetic trans-
mission and smooth muscle dyssynergia in the urethra.
These results suggest that the therapeutic eﬀect depends on both somatic and autonomic nerves.
In addition to classic neuropathic DESD, we have expanded the indications for use of botulinum A toxin to include patients with a variety of bladder outlet obstruc-
tions, excluding those patients with obstructions secon-
dary to ﬁbrosis. We have successfully used botulinum A
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Fig. 3  Current and potential future targets for botulinum toxin within the lower urinary tracts. BNO, bladder neck obstruction;BPH,
benign prostatic hyperplasia;DESD, detrusor external sphincter dyssynergia;DH, detrusor hyperreﬂexia;DISD, detrusor internal sphincter dyssynergia;IC, interstitial cystitis.
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toxin to treat voiding dysfunction in multiple sclerosis patients with DESD, patients with pelvic ﬂoor spasticity,
and even in an acontractile multiple sclerosis patient who wished to void by valsalva［20］. Recently, we reported a case of functional urethral obstruction and detrusor acontractility following pubovaginal sling surgery that was successfully treated by botulinum A toxin urethral sphinc-
ter injection［23］.
We perform Botox?urethral sphincter injections by mixing one vial(100 units)of Botox?with 10 cc of saline just prior to injection. It is important not to shake the vial,
as this may break the disulﬁde linkage between the light and heavy chains and render the toxin ineﬀective. Using a collagen injection needle(we prefer Cook?because of the sharper end), injections of 2.5 cc each are made at the 12, 3, 6, and 9 o’clock positions at the level of the striated sphincter. Injections must be directed deeper than collagen injections in order to target nerve terminals innervating skeletal muscle. We also ﬂush the needle with 0.2 cc of saline at the end of the procedure to ensure that no toxin is wasted.
Data have been ac-
cumulating on the clinical application of BTX-A to detrusor muscle in hyperreﬂexic bladders of spinal cord injured patients. A preliminary study by Schurch and colleagues in 31 patients with detrusor hyperreﬂexia demonstrated a signiﬁcant increase in mean maximum bladder capacity(296 ml to 480 ml, P＜0.016)and a signiﬁcant decrease in mean maximum detrusor voiding pressure (65 to 35 cm H?O, P＜0.016) in patients injected with BTX-A［5］. A follow-up, long-term study completed by the same investigators in 87 patients with detrusor hyperreﬂexia corroborated the eﬃcacy of intravesical botulinum toxin injection found in their earlier study［24］. In addition, they reported clinical responses lasting 4-14 months and observed no adverse eﬀects with treatment. Detrusor muscle injections were performed in over 30 sites with either 300 units of Botox?or 500-750 units of Dysport?. The trigone was spared, presumably,
to avoid the potential complication of vesicoureteral reﬂux.
In contrast, Del Popolo noted hyposthenia in 5/61 patients treated with high-dose intravesical BTX-A injec-
tions(300u of Botox?or 1000u Dysport?)［25］. The supralesional weakness was transient in nature, disappear-
ing 2-4 weeks after injection, and was abolished with lower dosage injections (500u Dysport?). Clearly, the dose and volume injected play a signiﬁcant role in inducing systemic toxicity with BTX-A. Multiple injections of
 
lower doses would be expected to have a more localized and less systemic eﬀect. However, the primary disadvan-
tage of intravesical BTX-A injections for many urologists is the repeated cystoscopies and toxin injections that are necessary to maintain clinical results.
BTX-A injections have extended beyond the realm of neurogenic bladders to patients with non neurogenic voiding and storage disorders. Radziszewski and associ-
ates reported favorably on the eﬀects of intravesical BTX-A injections in a pilot study of patients with either idiopathic bladder overactivity or functional outlet obstruc-
tion［26］. Following intravesical or sphincteric BTX-A injections, patients demonstrated a resolution of inconti-
nence and improved voiding eﬃciency, respectively.
Finally, Zermann and colleagues presented their experi-
ence with intravesical BTX-A injection in seven patients with severe urgency-frequency-syndrome refractory to anticholinergic therapy or electrical stimulation［27］. In contrast to other studies involving intravesical BTX-A injections, the authors’targeted the trigone and bladder base with 5-7 injections of 50, 100, or 200 units of Botox?. Four of seven patients responded to treatment with decreases in frequency and increased bladder capac-
ity. No mention was made of vesicoureteral reﬂux as a complication of treatment.
We recently presented a single surgeon’s experience using Botox?in the bladder and urethra in 50 patients for a variety of dysfunctions over the past 3 years［28］.
Between October of 1998 and October 2001, 50 patients
(age range 31-84)were injected with botulinum toxin into the bladder(n＝10)or urethra(n＝40). Of these, 19 were men and 31 were women. Voiding dysfunctions were a result of both neurogenic and non neurogenic conditions and included:multiple sclerosis, spinal cord injury, cerebral vascular accident, overactive bladder,
interstitial cystitis, and dysfunctional voiding. Procedures were performed using light sedation. Patients were treat-
ed with either 100 units of Botox?divided in equal doses into the 4 quadrants of the external sphincter, or via injection into the bladder base using 100-300 units of botulinum toxin diluted in 20 ml of sterile saline. Present-
ly, 15 of these patients have undergone further injections
(as many as 4)at intervals of 6 months or more.
Maximal eﬃcacy of botulinum injection was achieved within 7 days post injection. Analysis of the 50 patients indicates that 41 of 50 patients(82 )reported a decrease or absence of incontinence as well as a signiﬁcant decrease in voiding symptoms. Sleep quantity and quality in-
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creased in more than 50 of patients. Follow-up of these patients indicates that eﬀects lasted up to 12 months. No patient developed stress incontinence or urinary retention.
These latest clinical ﬁndings are supported by research of ours and others demonstrating the eﬃcacy of BoNTs on autonomic nerves［29-32］. Our study results indicate that the release of norepinephrine and acetylcholine was reduced by 60  and 64 , respectively in BoNT/
A-treated versus control rat bladders［32］.
Research Development
 
An interesting side eﬀect of patients with cervical dystonia injected with BTX-B (MyoblocTM, Elan)is the development of dry mouth［33］. In a rare occurrence following BTX-A treatment, dry mouth was unexpected because the sali-
vary glands were farther from the injection site than relatively unaﬀected lingual or lower facial muscles. This eﬀect indicates that BTX-B may have a greater aﬃnity for cholinergic nerves innervating the salivary glands rather than lingual or lower facial muscles or, alternatively, that there are more BTX-B receptors in salivary glands compared to muscles of the lower face and tongue.
Future studies should clarify whether similar eﬀects can be seen in parasympathetic cholinergic nerves innervating the lower urinary tract.
In addition, evidence from Carpenter’s experiments in the late 1960s as well as that from our lab suggests that rat bladders are signiﬁcantly more sensitive to the eﬀects of BoNT/D than BoNT/A［29, 34］. In fact, Carpenter has found that parasympathetic blockade with BoNT/D occurs before somatic neuromuscular blockade. It remains to be seen whether these eﬀects are merely due to diﬀering sensitivities of various cholinergic nerve endings to diﬀerent toxins, or whether BoNT/D’s greater eﬃcacy in the bladder is due to an eﬀect on non cholinergic transmission. Currently, no data exist regard-
ing whether these same diﬀerences in rat bladder sensitiv-
ity to toxin isoforms exist in the human bladder.
Several investigators have demonstrated in vitro evidence of an aﬀerent eﬀect of botulinum toxin. Welch and colleagues have reported that neuropeptide release from rat dorsal root ganglia is inhib-
ited by botulinum toxin(BoNT/A, B, C1, F)treatment,
while Purkiss and colleagues have noted that incubation of rat dorsal root ganglia with BoNT/A inhibits the release of radioactively labeled glutamate［35, 36］. The inhibi-
tion of transmitter release from nociceptive neurons could impair mechanisms involved with central sensitization and could position botulinum toxin as a therapeutic agent in conditions such as chronic pain.
Current in vivo studies support a role for BTX-A in relieving nociceptive pain. In a model of pain associated with formalin-induced inﬂammation, rats were pretreated in the hind paw with BTX-A prior to injection with formalin［37］. Formalin provokes pain via a direct stimulation of nociceptors (Phase 1)and, subsequently,
by inﬂammation(Phase II). Formalin was injected 5 and 12 days after BTX-A injection. Surrogate markers of pain included paw-licking and paw-lifting behavior.
Pretreatment with BTX-A signiﬁcantly reduced pain at 5 and 12 days post injection. These results support clinical observations that BTX-A has an antinociceptive eﬀect that is independent of its eﬀects on the neuromuscular junction.
We have preliminary results suggesting that BoNT/A treatment inhibits aﬀerent nerve mediated bladder strip contractions, presumably by blocking neurotransmitter release from peripheral aﬀerent nerve terminals in the bladder［38］. BoNT/A treatment was found to signiﬁcantly decrease aﬀerent nerve-mediated contractions in response to both electrical and chemical stimulation by 44.6  and 35.1 , respectively, compared to saline-
treated animals (P＜0.05).
In addition, we have clinical experience with Botox?
treatment in a 42-year-old female patient suﬀering from recalcitrant IC (personal observation). Under light seda-
tion, following hydrodistension with saline(80 cm)for 5 min, 100 units of Botox?, diluted in 100 ml of saline,
was instilled in the bladder and held for 30 min. The patient was discharged home the same day and followed up over the ensuing 6 months. One week following Botox?treatment, the patient noted a marked improve-
ment in her voiding symptoms, characterized by de-
creased frequency, urgency, and urge incontinent epi-
sodes. Nocturia decreased four fold, and painful bladder symptoms diminished greatly as evidenced by a 50 decrease in oral pain medication usage. On a visual analog scale, the patient’s bother score decreased from a 10 to a 5 following BTX-A treatment. Maximal therapeutic eﬀects lasted 3 months, with some improvement still noted at 6 months post treatment. Our preliminary ﬁndings may lead to new therapeutic applications of BTX-A such as treating conditions associated with in-
creased aﬀerent nerve excitability(i.e. spinal cord injury,
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chronic inﬂammation).
Clearly, BTX-A has a much wider spectrum of application within the urologic ﬁeld than merely the treat-
ment of DH and DESD in SCI patients. Treatment should be extended to other ﬁelds, including the MS population and those with non neurogenic voiding and storage disorders. Our basic research evidence that BoNT/A inhibits norepinephrine release in the rat bladder and urethra should prompt studies investigating the eﬀects of botulinum toxin on disorders of increased sympathetic activity (e.g. functional bladder neck obstruction,
detrusor internal sphincter dyssynergia, and BPH).
Finally, if aﬀerent nerve transmission is impaired by botulinum toxin, a signiﬁcant patient population will be opened up to this treatment(Fig. 3).
Conclusions
 
Since the 1980s, injection of botulinum toxin has proven to be a safe and eﬀective therapy for a variety of somatic and autonomic motor disorders. Urologists are now ﬁnding clinical success with urethral and bladder BTX-A injections in the treatment of detrusor-sphincter dyssynergia, non neurogenic pelvic ﬂoor spasticity, and refractory overactive bladder. Many interesting research questions remain regarding BTX’s eﬀects on the neural pathways of the lower urinary tract［39］. However, one cannot deny the ingenuity of man in transforming the lethal toxin of Clostridium botulinum into a modern-day therapeutic medicine.
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